{
    "clinical_study": {
        "@rank": "144779", 
        "arm_group": {
            "arm_group_label": "HAV Group", 
            "arm_group_type": "Experimental", 
            "description": "Subjects who were previously vaccinated with Havrix in primary studies."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the long-term persistence of immunity to hepatitis A\n      in adults who were vaccinated 21-25 years earlier with hepatitis A vaccine, Havrix\u00ae."
        }, 
        "brief_title": "Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix\u00ae", 
        "completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis A", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a long-term persistence study in which subjects who participated in the primary\n      studies HAV-112 (208109/108) or HAV-123 (208109/114) and did not receive an additional dose\n      of hepatitis A vaccine since then, will be invited to provide a blood sample at Years 21 to\n      25 after their second vaccine dose. No vaccine will be administered during the study period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A male or female who received two doses of Havrix in study HAV-112 (208109/108) or\n             HAV-123 (208109/114), and received no further booster dose since then.\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol (e.g. return for follow-up visits).\n\n          -  Written informed consent obtained from the subject.\n\n        Exclusion Criteria:\n\n          -  History of hepatitis A disease since completion of the primary vaccination series in\n             studies HAV-112 (208109/108) or HAV-123 (208109/114).\n\n          -  Administration of a hepatitis A vaccine at any time since completion of the primary\n             vaccination series in studies HAV-112 (208109/108) or HAV-123 (208109/114) including\n             a challenge dose of the study vaccine, as a part of the study procedures, during the\n             long-term persistence phase.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history.\n\n          -  Administration of hepatitis A immunoglobulins and/or any blood products and/or\n             long-acting immune-modifying drugs within six months prior to study entry.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within\n             six months prior to study entry. For corticosteroids, this will mean prednisone \u2265 20\n             mg/day, or equivalent. Inhaled and topical steroids are allowed.\n\n          -  Administration of long-acting immune-modifying drugs within six months prior to study\n             entry (e.g. infliximab).\n\n          -  Concurrently participating in another clinical study during the period starting 30\n             days before and ending 30 days after each study visit, in which the subject has been\n             or will be exposed to an investigational or a non-investigational vaccine/product\n             (pharmaceutical product or device)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124785", 
            "org_study_id": "116763", 
            "secondary_id": "2013-001918-15"
        }, 
        "intervention": {
            "arm_group_label": "HAV Group", 
            "description": "At Years 21 to 25 after their second vaccine dose.", 
            "intervention_name": "Blood sampling", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Hepatitis A Antibodies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Long-term persistence", 
            "Havrix", 
            "Hepatitis A"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "US GSK Clinical Trials Call Center", 
                "phone": "877-379-3718"
            }, 
            "contact_backup": {
                "email": "GSKClinicalSupportHD@gsk.com", 
                "last_name": "EU GSK Clinical Trials Call Center", 
                "phone": "+44 (0) 20 8990 4466"
            }, 
            "facility": {
                "address": {
                    "city": "Wilrijk", 
                    "country": "Belgium", 
                    "zip": "2610"
                }, 
                "name": "GSK Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix\u00ae (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114)", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Immunogenicity with respect to components of the study vaccine in terms of anti-HAV seropositivity status and GMCs.", 
            "safety_issue": "No", 
            "time_frame": "21 to 25 years after the second vaccine dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Occurrence of serious adverse events (SAEs).", 
            "safety_issue": "No", 
            "time_frame": "During the entire study period (Year 21 to Year 25)."
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}